Navigation Links
Statement from the Consumer Healthcare Products Association on Mississippi Bill that Limits Consumer Access to Cold and Allergy Medicines Containing Pseudoephedrine by Requiring a Prescription
Date:2/2/2010

WASHINGTON, Feb. 2 /PRNewswire-USNewswire/ -- The following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA), in response to Senate passage of legislation which will require a prescription to access over-the-counter cold and allergy medicines containing pseudoephedrine:

"We are disappointed that the Mississippi Senate chose to overlook consumer sentiment and passed a bill today that will significantly impact how cold and allergy sufferers access some of their medicines. While well-intentioned, this bill will impose an unnecessary burden on Mississippians, despite there being a better and more effective solution to address the state's meth production problem.

"Under this legislation, if only half of those Mississippians who rely on these medicines are now forced to visit a doctor to obtain a prescription for these cold and allergy medicines containing pseudoephedrine, the cost to the healthcare system would be over $7 million. Additional impacts to the state include a loss of over half-a-million dollars from lost sales tax revenue, and notable cost increases to the state's Medicaid program and state employee and retiree programs. In a time of economic scrutiny, this option is counterproductive in addressing the current crisis in healthcare delivery—especially among Mississippi's uninsured and medically underserved.

"In the short time that this debate has been underway, Mississippians have spoken out that this is not the right way to address methamphetamine abuse. From comments on media stories to calls to the state legislature, many consumers have expressed outrage that the state is rushing to push this law through—especially when a more effective alternative is on the table. Electronic tracking of over-the-counter medicines containing pseudoephedrine serves as a more effective, less-costly alternative, and one that eight states have adopted to fight domestic methamphetamine production while maintaining consumer access to these medicines. An e-tracking system is a tool that law enforcement and pharmacists can use to stop the sale of illegal amounts of pseudoephedrine as set forth by the federal Combat Methamphetamine Epidemic Act of 2005. With this real-time tracking system, states can also link up with other states to track cross-border sales."

CHPA is the 129-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and nutritional supplements.

www.chpa-info.org

SOURCE Consumer Healthcare Products Association

RELATED LINKS
http://www.chpa-info.org

'/>"/>

SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. AAPM statement on quality radiation therapy
2. Statement From American Heart Association CEO Nancy Brown on President Obamas State of the Union Address
3. Statement from the Consumer Healthcare Products Association on Mississippi Bill that Seeks to Make Cold, Allergy Medicines Containing Pseudoephedrine Prescription-Only
4. Statement from RC Cancer Centers Regarding News Story on Radiation Oncology
5. Statement From the American Health Care Association and National Center for Assisted Living in Anticipation of President Obamas State of the Union Address
6. SEIU-UHW Statement on Kaiser Union Election in Southern California
7. Operation Rescues Advisory Board Issues Statement on Mr. Terrys Extremism
8. Statement: Helping the UN Help Haiti
9. Pelosi Statement on New Report That Health Reform Will Create 4 Million More Jobs Over the Next Decade
10. Statement by Blue Shield of California CEO Bruce Bodaken Regarding the Groundbreaking for the Family Violence Prevention Funds International Center
11. Statement of US Secretary of Labor Hilda L. Solis on December 2009 employment numbers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: